CRIS
CRIS clinical trials: CURIS INC
Every trial on ClinicalTrials.gov where CURIS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 19
- Trials linked
- 13
- As lead sponsor
- 6
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CRIS on the catalyst calendar · CRIS registry changes
- Primary completion Jul 2027Sponsor estimatePhase 1/Phase 2NCT03328078CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous...Curis, Inc. · Relapsed Hematologic MalignancyRecruitingCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and...Curis, Inc. · Chronic Lymphocytic LeukemiaRecruitingCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2026Sponsor estimatePhase 1/Phase 2NCT04278768Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome...Curis, Inc. · Acute Myelogenous LeukemiaSuspendedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 19, 2023ActualPhase 1NCT04475523Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor MalignanciesCuris, Inc. · Solid TumorCompletedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2019ActualPhase 2NCT02674750Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC AlterationsCuris, Inc. · Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc AlterationsCompletedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 9, 2020ActualPhase 1NCT01742988Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaCuris, Inc. · LymphomaCompletedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 7, 2020ActualPhase 1NCT02812875A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and LymphomasCuris, Inc. · Advanced Solid Tumors or LymphomasCompletedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2019ActualPhase 1NCT02307240Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed...Curis, Inc. · Triple-Negative Breast CancerCompletedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2013ActualPhase 1NCT01384799Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck CancerCuris, Inc. · Head and Neck CancerCompletedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2010ActualPhase 1NCT00728793A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid TumorsCuris, Inc. · TumorsCompletedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2012ActualPhase 1NCT01702285Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer PatientsCuris, Inc. · CancerTerminatedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2015ActualPhase 1NCT01908413Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory...Curis, Inc. · LymphomaTerminatedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 1NCT01171924A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced...Curis, Inc. · Head and Neck CancerCompletedCRISLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2022ActualEarly Phase 1NCT03893487Fimepinostat in Treating Brain Tumors in Children and Young AdultsSabine Mueller, MD, PhD · Diffuse Intrinsic Pontine GliomaCompletedCRISCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2028Sponsor estimatePhase 1NCT05187182CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerWashington University School of Medicine · Gastric CancerRecruitingCRISCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2030Sponsor estimatePhase 1NCT07107750Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic...Washington University School of Medicine · Metastatic Biliary Tract CancerRecruitingCRISCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025ActualPhase 1NCT02909777Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaDana-Farber Cancer Institute · LymphomaCompletedCRISCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2024ActualPhase 2NCT05178342Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948University of Leipzig · Myelodysplastic SyndromesTerminatedCRISCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 3NCT00004487Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients With Vesicoureteral RefluxFDA Office of Orphan Products Development · Vesicoureteral RefluxUnknown statusCRISCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 19 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner